Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Asparagine Synthetase Resistance Research and Metabolic Oncology.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ASNS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ASNS Recombinant Protein (Full Length, Active Enzyme) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View ASNS Products |
| Gene Delivery | ASNS Lentivirus Premade Particles Full-length ORF for stable cell lines and rescue experiments. High titer (>10^8 TU/ml). |
View ASNS Products |
| Benchmark Ab | Anti-ASNS Monoclonal Antibody Sequence Verified, suitable for WB/IHC detection standards and target engagement. |
View ASNS Products |
| Validator | ASNS siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View ASNS Products |
| Related Target: GLS | Glutaminase (GLS) Synergistic metabolic node; glutamine-dependent amino acid synthesis pathway. |
View GLS Products |
| Related Target: ASS1 | Argininosuccinate Synthetase (ASS1) Synthetic lethality benchmark; metabolic auxotrophy resistance paradigm. |
View ASS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Assay (Active conformation required) | HEK293 Expressed protein with native folding; Sequence Verified; High Purity (>95%) for kinetic studies |
| Cross-species correlation (Mouse/Human) | Human and Mouse ASNS orthologs available with matched specifications; >95% purity for comparative pharmacology |
| Resistance Mechanism Validation | Lentivirus for Stable Cell Line construction (overexpression models); siRNA for knockdown confirmation |
| Biomarker Validation (Expression) | Sequence Verified benchmark antibodies for reliable IHC/WB to assess L-asparaginase sensitivity |
| Lack of Expression Controls | Sequence-verified recombinant protein (WT & mutant variants) included as Western Blot/IHC positive control |
Live ASNS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The understanding of ASNS (Asparagine Synthetase) biology is reshaping therapeutic strategies in hematological malignancies, particularly as a predictive biomarker for L-asparaginase resistance. As first-generation asparagine-depleting therapies reach maturity, the next wave of R&D focuses on ASNS expression-guided patient stratification and synthetic lethal combinations targeting metabolic vulnerabilities. Tumors upregulate ASNS under amino acid deprivation stress via the GCN2/ATF4 pathway, driving interest in small molecule ASNS inhibitors and targeted protein degraders (PROTACs) to achieve synthetic lethality in ASNS-dependent cancers. High-purity ASNS reagents are critical for developing companion diagnostics and understanding resistance mechanisms in Acute Lymphoblastic Leukemia (ALL) and solid tumors with asparagine auxotrophy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Biomarker Development | St. Jude Children's Research Hospital, Academic Medical Centers | ALL, AML | Quantitative ASNS Protein Standards (High purity recombinant antigen for assay calibration) |
| Metabolic Inhibitor Combo | Takeda, Jazz Pharmaceuticals (Resistance Studies) | Relapsed/Refractory ALL | Cell-based Resistance Models (Lentivirus for stable ASNS overexpression lines) |
| Synthetic Lethality | Genentech, Novartis (Metabolic Programs) | Solid Tumors (ASNS-low subsets) | Knockdown Validation Assays (siRNA sets for synthetic lethality confirmation) |
| Small Mol Inhibitor / PROTAC | Academic/Biotech Consortia, Emerging Biotechs | Refractory Leukemia, Pancreatic Cancer, Chemo-resistant Solid Tumors | High-throughput Enzymatic Assay (Need Active ASNS Protein); Ternary Complex Validation (Need High-Purity Proteins) |